Want to see PPCB full AI Analyst Report?
PPCB Stock Chart & Stats
$1.01
$0.00(0.00%)
At close: 4:00 PM EST
$1.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.47 - $52.50
Previous CloseN/A
Volume127.03K
Average Volume (3M)3.62M
Market Cap
$3.24M
Enterprise Value$4.64
Total Cash (Recent Filing)$832.01K
Total Debt (Recent Filing)$509.12K
Price to Earnings (P/E)―
Beta-0.82
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.63
Shares Outstanding6,331,116
10 Day Avg. Volume363,499
30 Day Avg. Volume3,621,793
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet RepairThe sharp reduction in debt and return to positive equity provide a stronger financial base than the company had in earlier years. Lower leverage can reduce balance-sheet pressure and preserve flexibility while Propanc advances its oncology programs, although continued losses remain a constraint.
PRP Clinical AdvancementProgressing PRP toward a Phase 1b first-in-human study would represent an important development step for Propanc’s core oncology platform. A clinical program covering multiple advanced solid tumors could create a clearer path toward validating the candidate and building future strategic value.
Experienced Financial GovernanceAdding a director with senior finance, capital-raising, planning, and governance experience can strengthen oversight at a company that remains dependent on funding. His background may support more disciplined financial strategy as Propanc manages clinical development and corporate requirements.
Bears Say
Pre-Commercial BusinessNo revenue across six annual periods shows that Propanc remains pre-commercial and has not yet demonstrated a recurring income engine. Business value therefore depends heavily on successful development and eventual commercialization of its oncology candidates rather than established customer demand.
Persistent Cash BurnConsistently negative operating and free cash flow indicate that the business cannot currently fund operations from internally generated cash. The materially higher 2026 burn increases reliance on external financing and could limit the pace or continuity of future clinical development.
Deep Volatile LossesLarge and volatile net losses weaken financial resilience and make future profitability difficult to assess because there is still no revenue base. If losses continue, equity can erode further and the company may need additional funding before its oncology pipeline can generate commercial returns.
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $0.47 and its highest was $52.50 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $3.24M.
When is Propanc Biopharma’s upcoming earnings report date?
Propanc Biopharma’s upcoming earnings report date is Nov 23, 2026 which is in 53 days.
How were Propanc Biopharma’s earnings last quarter?
Propanc Biopharma released its earnings results on Sep 29, 2026. The company reported -$1.381 earnings per share for the quarter.
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 6,331,116 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Propanc Biopharma reported an EPS of -$1.381 in its last earnings report. Following the earnings report the stock price went down -3.94%.
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Propanc Biopharma
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
3.67% Other Institutional Investors
96.33% Public Companies and
Individual Investors